MX2010005012A - Compositions for the treatment and prevention of eyelid swelling. - Google Patents

Compositions for the treatment and prevention of eyelid swelling.

Info

Publication number
MX2010005012A
MX2010005012A MX2010005012A MX2010005012A MX2010005012A MX 2010005012 A MX2010005012 A MX 2010005012A MX 2010005012 A MX2010005012 A MX 2010005012A MX 2010005012 A MX2010005012 A MX 2010005012A MX 2010005012 A MX2010005012 A MX 2010005012A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
compositions
eyelid swelling
eyelid
Prior art date
Application number
MX2010005012A
Other languages
Spanish (es)
Inventor
Matthew Jonathan Chapin
Mark Barry Abelson
Keith Jeffrey Lane
George Minno
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of MX2010005012A publication Critical patent/MX2010005012A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
MX2010005012A 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling. MX2010005012A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US751107P 2007-11-08 2007-11-08
PCT/US2008/012513 WO2009061431A2 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor

Publications (1)

Publication Number Publication Date
MX2010005012A true MX2010005012A (en) 2010-06-23

Family

ID=40329067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005012A MX2010005012A (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling.

Country Status (8)

Country Link
EP (1) EP2219630A2 (en)
JP (1) JP2011503061A (en)
CN (1) CN101977595A (en)
AU (1) AU2008325214A1 (en)
BR (1) BRPI0819105A2 (en)
CA (1) CA2705050A1 (en)
MX (1) MX2010005012A (en)
WO (1) WO2009061431A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9173945B2 (en) * 2011-11-01 2015-11-03 Rohto Pharmaceutical Co., Ltd. Ophthalmological aqueous composition
EA021247B1 (en) * 2012-03-26 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
EA021234B1 (en) * 2012-03-27 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
JP6373551B2 (en) * 2012-05-30 2018-08-15 味の素株式会社 Gallotannin-containing composition
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014182610A2 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
JP2019509330A (en) 2016-01-26 2019-04-04 レベーション ファーマ リミテッド Alpha adrenergic agonist composition and use
EP3970803A1 (en) * 2020-09-22 2022-03-23 Beiersdorf AG Cosmetic composition of low osmolality
WO2022187306A1 (en) * 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2618428A (en) * 1947-01-27 1952-11-18 John K M Harrison Shock resistant container
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
IT1248014B (en) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa PROTRACTED OPHTHALMIC PREPARATIONS
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
JP2001187728A (en) * 1999-12-28 2001-07-10 Lion Corp Ophthalmic composition
DE10000612A1 (en) * 2000-01-10 2001-07-19 Min Becker Aqueous active substance preparations, especially eye drops, nasal drops and nasal sprays, contain sodium chloride in place of preservatives
JP2002308775A (en) * 2001-04-06 2002-10-23 Rohto Pharmaceut Co Ltd External composition
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
PT2377557T (en) * 2004-11-24 2017-02-07 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
JP2006232792A (en) * 2005-02-21 2006-09-07 Aile De Beaute:Kk Skin ageing-improving cosmetic
CN102895234A (en) * 2006-03-31 2013-01-30 维斯塔肯药品有限责任公司 Ocular allergy treatments
EP2015733A2 (en) * 2006-04-26 2009-01-21 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling

Also Published As

Publication number Publication date
CA2705050A1 (en) 2009-05-14
CN101977595A (en) 2011-02-16
AU2008325214A1 (en) 2009-05-14
EP2219630A2 (en) 2010-08-25
BRPI0819105A2 (en) 2019-09-24
JP2011503061A (en) 2011-01-27
WO2009061431A2 (en) 2009-05-14
WO2009061431A3 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2010005012A (en) Compositions for the treatment and prevention of eyelid swelling.
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
MX2010003258A (en) Use of a novel natural agent in cosmetic compositions.
MX2009009463A (en) Fast-dissolving/disintegrating film preparation having high proportion of active.
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX2009004038A (en) Diclofenac gel.
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
TW200716088A (en) Formulations and methods for treating amyloidosis
HK1140940A1 (en) Titration of tapentadol
JO3358B1 (en) Ocular Allergy Treatments
MX2009003911A (en) Enhanced immediate release formulations of topiramate.
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
MX2010005589A (en) Personal care composition.
MX2010001449A (en) Bupropion hydrobromide and therapeutic applications.
MX2010001300A (en) Use of hesperidin or of a derivative thereof for the prevention and/or treatment of slackened skin.
WO2009032843A3 (en) Deuterated ethambutols and their use
MX2009012370A (en) Low-viscous anthracycline formulation.
TW200730190A (en) New combination to treat liver fibrosis
PL1713438T3 (en) Medicinal soap
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
EA200801890A1 (en) MEANS FOR THE TREATMENT OF NOISE IN THE EARS
WO2006089218A3 (en) Methods and compositions for modulating angiogenesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal